semaglutide and duloxetine delayed-release capsules are being voluntarily recalled by Breckenridge Pharmaceutical, Inc. because it may contain elevated levels of a cancer-causing substance. Click the LINK IN BIO to read more Cymbalta: Side Effects, Withdrawal Symptoms

Description

Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D)

Semaglutide doesn't directly accelerate metabolism, but it fundamentally changes how your body regulates hunger and energy use, making weight loss more sustainable

I farmaci agonisti del GLP-1, un ormone coinvolto nella regolazione di appetito e glicemia, ne simulano lazione e vengono usati per trattare diabete e obesit.